Supportive Care in Cancer

, Volume 20, Issue 8, pp 1815–1822

Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis

Authors

  • Yan Jin
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Xiaomin Wu
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Yanmeng Guan
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Dongying Gu
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Yue Shen
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Zhi Xu
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
  • Xiaowei Wei
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
    • Department of OncologyThe Affiliated Nanjing First Hospital, Nanjing Medical University
Original Article

DOI: 10.1007/s00520-011-1280-z

Cite this article as:
Jin, Y., Wu, X., Guan, Y. et al. Support Care Cancer (2012) 20: 1815. doi:10.1007/s00520-011-1280-z

Abstract

Purpose

A number of studies have reported that aprepitant has been used to prevent chemotherapy-induced nausea and vomiting. In this study, we aimed to analyze the efficacy and safety of aprepitant, which can provide evidence for aprepitant administration.

Materials and methods

Fifteen trials involving patients who received moderately or highly emetogenic chemotherapy were included in this pooled analysis. Antiemetic drugs in these studies included aprepitant, dexamethasone, and 5-HT3 receptor antagonists.

Results

A total of 4,798 cases were investigated in these clinical trials. Compared with placebo or the standard antiemetic therapy, the cumulative incidence of emesis was significantly reduced in the patients treated with aprepitant-based (125 mg/80 mg) therapy on the first day [relative risk (RR) = 1.13, 95% confidence interval (CI) 1.10–1.16], from 2 to 5 days (RR = 1.35, 95% CI 1.22–1.48) and in the overall 5 days (RR = 1.30, 95% CI 1.22–1.39). In terms of drug safety, there was no significant difference between aprepitant-based regimens and non-aprepitant regimens.

Conclusion

Results from the analysis suggest that aprepitant with 5-HT3 receptor antagonists and dexamethasone is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy (MEC or HEC) agents.

Keywords

AprepitantNK-1 receptor antagonistsChemotherapy-induced nausea and vomitingPooled analysis

Copyright information

© Springer-Verlag 2011